- Home
- WPP vs TNGX Comparison
WPP vs TNGX Comparison
Compare WPP & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WPP | TNGX |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.1B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WPP | TNGX |
|---|---|---|
| Price | $25.22 | $24.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $23.83 | ★ $45.18 |
| AVG Volume (30 Days) | 275.3K | ★ 2.5M |
| Earning Date | 08-06-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.96 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $14.81 | $6.69 |
| 52 Week High | $27.78 | $34.39 |
Technical Indicators
Market Signals| Indicator | WPP | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 55.12 |
| Support Level | $25.70 | $19.74 |
| Resistance Level | $26.28 | $26.05 |
| Average True Range (ATR) | 0.56 | 1.53 |
| MACD | -0.11 | 0.29 |
| Stochastic Oscillator | 65.87 | 85.77 |
Price Performance
Historical ComparisonAbout WPP WPP plc
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.